Migrastatics—anti-Metastatic and Anti-invasion Drugs: Promises and Challenges

Aneta Gandalovičová, Daniel Rosel, Michael Fernandes, Pavel Veselý, Petr Heneberg, Vladimír Čermák, Luboš Petruželka, Sunil Kumar, Victoria Sanz-Moreno, Jan Brábek

Research output: Contribution to journalArticlepeer-review

256 Citations (Scopus)
229 Downloads (Pure)


In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term ‘migrastatics’ for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers.
Original languageEnglish
Pages (from-to)391-406
JournalTrends in Cancer
Issue number6
Publication statusE-pub ahead of print - 20 May 2017


  • solid cancer
  • metastasis
  • invasion
  • treatment
  • contractility
  • migrastatics


Dive into the research topics of 'Migrastatics—anti-Metastatic and Anti-invasion Drugs: Promises and Challenges'. Together they form a unique fingerprint.

Cite this